CORRECTION

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

Bob Geng · Adelaide A. Hebert · Liza Takiya · Lauren Miller ·
John L. Werth · Chuanbo Zang · Paul Sanders · Mark G. Lebwohl

Published online: September 22, 2021
© The Author(s) 2021

Correction to: Dermatol Ther (Heidelb)
<https://doi.org/10.1007/s13555-021-00584-y>

In Table 3, the value for dermatitis atopic should be “2 (1.5)” instead of 2 (2.5).
The original article has been corrected.

Authors would like to correct the error in their publication.

The original article can be found online at <https://doi.org/10.1007/s13555-021-00584-y>.

B. Geng
Division of Allergy, Immunology, and
Rheumatology, Department of Pediatrics, UC San
Diego School of Medicine, San Diego, CA, USA

A. A. Hebert
Department of Dermatology, UTHealth McGovern
School of Medicine, Houston, TX, USA

L. Takiya (✉) · J. L. Werth · C. Zang
Pfizer Inc., Collegeville, PA, USA
e-mail: liza.takiya@pfizer.com

L. Miller
Dermatology Specialists, Gadsden, AL, USA

P. Sanders
Pfizer R&D UK Ltd., Tadworth, Surrey, UK

M. G. Lebwohl
Department of Dermatology, Icahn School of
Medicine at Mount Sinai, New York, NY, USA

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.